That company,
Intrexon (NYSE: XON),
has been developing a set of tools that enable scientists to step
inside the human gene and alter its basic structure. The company isn't
concerned about coming up with a blockbuster drug. It wants to provide
the tools for other biotech firms to make major breakthroughs. So what
exactly is Intrexon looking to accomplish? The company is in the field
of synthetic biology, which alters the core mechanisms of action taking
place inside cell walls.
Make no mistake, this is an approach that will take time to pay off.
Intrexon must sign partnerships that promise upfront licensing fees
along with product-based royalties. In that respect, Intrexon is
starting to gain steam:
-- In October 2012, Intrexon inked a deal with Fibrocell to
supply the UltraVector platform to Fibrocell's dermatology and
aesthetics products.
(more)
Please share this article
No comments:
Post a Comment